Antitumor and anti-migratoty effects of Lurbinectedin on B-cells from chronic lymphocytic leukemia patients

RISNIK, DENISE; ENRIQUE PODAZA; COLADO, ANA; ELÍAS, ESTEBAN ENRIQUE; BEZARES, RAIMUNDO FERNANDO; FERNÁNDEZ GRECCO, HORACIO; BORGE, MERCEDES; CARLOS M. GALMARINI; GAMBERALE, ROMINA; GIORDANO, MIRTA

Workshop; XIth International Workshopof the German CLL Study Group; 2018

Lurbinectedin (Lur) is a synthetic alkaloid that induces DNA damage even in quiescent cells and iscurrently in phase II/III clinical trials for solid tumors. We aimed to evaluate the cytotoxicity of Lur oncirculating mononuclear cells (PBMC) from CLL patients and healthy donors and to determine whetherit could alter the cross-talk of CLL cells and tumor microenvironment. By flow cytometry analysis, wefound that Lur induced a dose- and time-dependent death of all cell types, being B cells and monocytesthe most susceptible populations at clinical relevant doses (Lur ≤ 10 nM). Interestingly, nurse like cellsdifferentiated in vitro from CLL-monocytes showed a greater resistance compared to monocytes (p